Targeting and activation of macrophages in leishmaniasis. A focus on iron oxide nanoparticles

Carmen Palomino-Cano1, Esther Moreno1, Juan M Irache1,2

  • 1Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain.

Frontiers in Immunology
|August 30, 2024
PubMed

Insights

Iron oxide nanoparticles (IONPs) show promise for treating leishmaniasis by reprogramming M2 macrophages to M1, enhancing parasite elimination. This immunotherapy targets iron metabolism to boost macrophage antimicrobial activity.

Area of Science:

  • Immunology
  • Parasitology
  • Nanomedicine

Background:

  • Macrophages are key hosts for Leishmania parasites, with adaptable phenotypes (M1 vs. M2).
  • Leishmania manipulates macrophages to an M2, parasite-permissive state, hindering eradication.
  • Iron is crucial for both host and parasite, influencing macrophage function and phenotype.

Purpose of the Study:

  • To explore the interplay between macrophages, Leishmania, and iron.
  • To investigate iron oxide nanoparticles (IONPs) as a therapeutic strategy for leishmaniasis.

Main Methods:

  • Review of existing literature on macrophage-Leishmania interactions and iron metabolism.
  • Focus on the potential of IONPs to reprogram M2 macrophages to an M1 phenotype.

Main Results:

  • Leishmania actively promotes M2 macrophage polarization, facilitating parasite survival.
  • Iron competition influences macrophage defense and phenotype.
  • IONPs demonstrate potential for reprogramming M2 macrophages to M1.

Conclusions:

  • IONPs offer a novel immunotherapy approach for leishmaniasis.
  • Targeting macrophage iron metabolism with IONPs can enhance parasite clearance.
  • This strategy modulates host-parasite interactions for improved leishmaniasis treatment.